TABLE 3.
Clinical course of the late (8–30 days) post-vaccination period in pregnant women
| Clinical sign |
Group I Agrippal S1 |
Group II Grippol Plus |
Group III Placebo |
| Total subjects | 37 | 42 | 41 |
| Local reactions | |||
| Pain at the injection site | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Hyperaemia at the injection site | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Sealing at the injection site | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Systemic reactions | |||
| Enhanced temperature | 2 (5.4) | 4 (9.5) | 4 (9.8) |
| Fatigability | 10 (27.0) | 8 (19.0) | 7 (17.1) |
| Arthralgia | 2 (5.4) | 2 (4.8) | 1 (2.4) |
| Myalgia | 2 (5.4) | 3 (7.1) | 1 (2.4) |
| Headache | 12 (32.4) | 10 (23.8) | 10 (24.4) |
| Dizziness | 4 (10.8) | 5 (11.9) | 6 (14.6) |
| Nausea | 5 (13.5) | 8 (19.0) | 8 (19.5) |
| Stomach ache | 7 (18.9) | 7 (16.7) | 6 (14.6) |
| Diarrhoea | 3 (8.1) | 4 (9.5) | 3 (7.3) |
| Infection | |||
| Cough | 4 (10.8) | 7 (16.7) | 7 (17.1) |
| Pain in the throat | 8 (21.6) | 8 (19.0) | 7 (17.1) |
Data are presented as n or n (%). Note that p>0.05 for the differences between the compared groups.